Renaissance Technologies LLC Increases Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,531,498 shares of the specialty pharmaceutical company’s stock after purchasing an additional 113,300 shares during the quarter. Renaissance Technologies LLC owned approximately 4.68% of Collegium Pharmaceutical worth $49,314,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 3.3% in the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 281 shares during the period. Louisiana State Employees Retirement System boosted its holdings in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after acquiring an additional 300 shares during the period. Texas Permanent School Fund Corp grew its position in shares of Collegium Pharmaceutical by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 369 shares during the last quarter. SummerHaven Investment Management LLC increased its holdings in shares of Collegium Pharmaceutical by 1.3% in the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 452 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 535 shares during the period.

Collegium Pharmaceutical Trading Up 0.7 %

NASDAQ COLL opened at $37.38 on Wednesday. Collegium Pharmaceutical, Inc. has a 52-week low of $20.95 and a 52-week high of $40.95. The firm has a 50-day moving average price of $35.65 and a 200 day moving average price of $35.41. The stock has a market capitalization of $1.20 billion, a P/E ratio of 15.58 and a beta of 0.94. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same period last year, the firm earned $1.13 EPS. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.82 EPS for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on COLL shares. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price objective for the company from $41.00 to $44.00 in a research note on Friday, June 7th. HC Wainwright lifted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Finally, Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.